Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler

@article{Rohatagi2004PharmacoscintigraphicCO,
  title={Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler},
  author={S. Rohatagi and S. Chapel and S. Kirkesseli and S. Newman and J. Zhang and D. Paccaly and Linda Randall and H. Wray and S. Wellington and B. Shah and B. Jensen},
  journal={American Journal of Therapeutics},
  year={2004},
  volume={11},
  pages={103-113}
}
A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031 from the existing nebulizer formulation and the new Ultrahaler device to help determine the doses for future phase 2 trials. This was a single-dose, open-label, randomized, two-way crossover study in which HMR 1031 (3 mg) was delivered by the Ultrahaler and the Pari LC Star nebulizer to 12 healthy male subjects. For both treatments, the formulations were radiolabeled with technetium-99m pertechnetate such… Expand
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
Adhesion molecules as therapeutic targets.
  • B. Bochner
  • Medicine
  • Immunology and allergy clinics of North America
  • 2004
Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma
  • Z. Diamant, J. Kuperus, +9 authors J. Prins
  • Medicine
  • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2005

References

SHOWING 1-10 OF 26 REFERENCES
Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler.
Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort.
Lung deposition from four nebulizers.
...
1
2
3
...